Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00191906
First received: September 12, 2005
Last updated: May 17, 2010
Last verified: May 2010
Results First Received: December 11, 2008  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Attention Deficit Hyperactivity Disorder
Reading Disorder
Interventions: Drug: Atomoxetine Hydrochloride
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Period I: screening/washout (89 patients screened, 13 screen-failures;45 controls screened). Period II (Visits 2-5): patients received treatment for 4 weeks and then underwent 2-week washout period after which they crossed over to receive the alternate treatment for 4 additional weeks. Period III (Visits 6-12): optional open-label (1 country only).

Reporting Groups
  Description
Atomoxetine First, Then Placebo Atomoxetine 1.2 mg/kg/day, by mouth for 4 weeks, 2 week washout period and then cross-over to placebo, every day, by mouth for 4 weeks.
Placebo First, Then Atomoxetine Placebo every day, by mouth for 4 weeks, 2 week washout period and then cross-over to atomoxetine 1.2 mg/kg/day, by mouth for 4 weeks.
Normal Control Untreated normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population.
Reading Disordered Control Untreated reading disordered control group was comprised of children with reading disorder who received standard remedial teaching therapy.

Participant Flow for 2 periods

Period 1:   Study Period II
    Atomoxetine First, Then Placebo   Placebo First, Then Atomoxetine   Normal Control   Reading Disordered Control
STARTED   39   37   27   18 
COMPLETED   39   32   26   18 
NOT COMPLETED   0   5   1   0 
Adverse Event                0                1                0                0 
Withdrawal by Subject                0                3                0                0 
Parent/Caregiver Decision                0                1                0                0 
Entry Criteria Exclusion                0                0                1                0 

Period 2:   Study Period III
    Atomoxetine First, Then Placebo   Placebo First, Then Atomoxetine   Normal Control   Reading Disordered Control
STARTED   14 [1]   11 [1]   0   0 
COMPLETED   9   7   0   0 
NOT COMPLETED   5   4   0   0 
Adverse Event                1                0                0                0 
Lost to Follow-up                0                1                0                0 
Parent/Caregiver Decision                1                0                0                0 
Lack of Efficacy                3                3                0                0 
[1] These are patients who continued in optional open-label period (1 country). All received atomoxetine



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Atomoxetine First, Then Placebo Atomoxetine 1.2 mg/kg/day for 4 weeks, 2 week washout, and then placebo for 4 weeks
Placebo First, Then Atomoxetine Placebo for 4 weeks, 2 week washout, and then atomoxetine 1.2 mg/kg/day for 4 weeks.
Normal Control Untreated normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population.
Reading Disordered Control Untreated reading disordered control group was comprised of children with reading disorder who received standard remedial teaching therapy.
Total Total of all reporting groups

Baseline Measures
   Atomoxetine First, Then Placebo   Placebo First, Then Atomoxetine   Normal Control   Reading Disordered Control   Total 
Overall Participants Analyzed 
[Units: Participants]
 39   37   27   18   121 
Age 
[Units: Years]
Mean (Standard Deviation)
 10.0  (1.34)   9.9  (1.25)   9.9  (1.01)   10.6  (0.99)   10.0  (1.2) 
Gender 
[Units: Participants]
         
Female   13   10   10   5   38 
Male   26   27   17   13   83 
Region of Enrollment 
[Units: Participants]
         
Belgium   18   15   0   16   49 
Netherlands   21   22   27   2   72 
Study Arm - Diagnosis 
[Units: Participants]
         
ADHD-Combined Type   13   15   0   0   28 
Reading Disorder   11   12   0   18   41 
ADHD-Combined Type + Reading Disorder   15   10   0   0   25 
No Disorder   0   0   27   0   27 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

2.  Secondary:   Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset   [ Time Frame: Baseline and 4 weeks of therapy ]

3.  Secondary:   Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset   [ Time Frame: Baseline and 4 weeks of therapy ]

4.  Secondary:   Lexical Decision Task Mean Reaction Time: Correct Words   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

5.  Secondary:   Lexical Decision Task Mean Reaction Time: Pseudo Words   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

6.  Secondary:   Working Memory by Corsi Block Tapping Test (CBTT)   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

7.  Secondary:   Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total Score   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

8.  Secondary:   Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Inattention Subscale   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

9.  Secondary:   Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Hyperactivity-Impulsivity Subscale   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

10.  Secondary:   Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total T-Score   [ Time Frame: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy ]

11.  Secondary:   Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale   [ Time Frame: 4 week therapy endpoint ]

12.  Secondary:   Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale   [ Time Frame: 4 week therapy endpoint ]

13.  Secondary:   Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudohomophones   [ Time Frame: Baseline and 4 weeks of therapy ]

14.  Secondary:   Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudo Words   [ Time Frame: Baseline and 4 weeks of therapy ]

15.  Secondary:   Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudohomophones   [ Time Frame: Baseline and 4 weeks of therapy ]

16.  Secondary:   Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudo Words   [ Time Frame: Baseline and 4 weeks of therapy ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Eli Lilly and Company
phone: 1-800-545-5979


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Chief Medical Officer, Eli Lilly
ClinicalTrials.gov Identifier: NCT00191906     History of Changes
Other Study ID Numbers: 7955
B4Z-MC-LYCK ( Other Identifier: Eli Lilly and Company )
Study First Received: September 12, 2005
Results First Received: December 11, 2008
Last Updated: May 17, 2010